Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04367740 · ClinicalTrials.gov registry record
ScreenNC, a Study to Determine the Number of Asymptomatic Individuals Who Have Antibodies to the Virus That Causes COVID-19
A clinical trial, sponsored by University of North Carolina, Chapel Hill.
- Completed
- Registry status
- 6,313
- Enrollment target
NCT04367740: Completed study, sponsored by University of North Carolina, Chapel Hill.
NCT04367740 is a clinical trial that has completed, run by University of North Carolina, Chapel Hill. The registered enrollment target is 6,313 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04367740 has completed, sponsored by University of North Carolina, Chapel Hill.
- COMPLETED
- Registry status
- 6,313 participants
- Enrollment target
Study Summary
Purpose: To determine the number of asymptomatic individuals who have antibodies to SARS-CoV-2, the virus which causes COVID-19
Primary Outcome
Presence or absence of IgG antibodies to SARS-CoV2
Interventions
- DIAGNOSTIC_TEST To assess for development of IgG antibodies against SARS-CoV2
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6,313 participants |
| Start Date | 2020-04-28 |
| Est. Completion | 2022-02-28 |
What the finished NCT04367740 record still lists
NCT04367740 is an observational study that tracks outcomes without assigning an intervention. Its 6,313 participants enrollment target places it among the larger protocols in the corpus.
The record links to 0 conditions, and to 1 intervention - of which To assess for development of IgG antibodies against SARS-CoV2 is the first listed.
NCT04367740 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04367740 about?
NCT04367740 is a clinical study titled "ScreenNC, a Study to Determine the Number of Asymptomatic Individuals Who Have Antibodies to the Virus That Causes COVID-19". Purpose: To determine the number of asymptomatic individuals who have antibodies to SARS-CoV-2, the virus which causes COVID-19
What is the current status of trial NCT04367740?
This trial is currently completed. The enrollment target is 6,313 participants. The study started on 2020-04-28. Estimated completion is 2022-02-28.
What interventions are being tested in trial NCT04367740?
The interventions under investigation include: To assess for development of IgG antibodies against SARS-CoV2 (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT04367740?
This trial is sponsored by University of North Carolina, Chapel Hill, which has 1,109 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04884802 · 6,254 participants · NA
The GUARDIAN Trial
- NCT03960099 · 6,250 participants · NA
Pictographs for Preventing Wrong-Patient Errors in NICUs
- NCT05440851 · 6,250 participants · NA
Platform of Randomized Adaptive Clinical Trials in Critical Illness
- NCT06566170 · 6,250 participants
A Real-World Comparative Study of Donanemab (LY3002813) Plus Usual Care Versus Usual Care Alone in US Participants With Early Symptomatic Alzheimer's Disease
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI